Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells by Nakajima, Taiki & Ikeya, Makoto
Title
Insights into the biology of fibrodysplasia ossificans
progressiva using patient-derived induced pluripotent stem
cells
Author(s)Nakajima, Taiki; Ikeya, Makoto




© 2019, The Japanese Society for Regenerative Medicine.
Production and hosting by Elsevier B.V. This is an open access






Insights into the biology of ﬁbrodysplasia ossiﬁcans progressiva using
patient-derived induced pluripotent stem cells*
Taiki Nakajima a, Makoto Ikeya b, *
a Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan
b Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan
a r t i c l e i n f o
Article history:
Received 29 January 2019
Received in revised form
18 March 2019
Accepted 5 April 2019
Keywords:
Fibrodysplasia ossiﬁcans progressiva




a b s t r a c t
The demand for development of new drugs remains on the upward trend because of the large number of
patients suffering from intractable diseases for which effective treatment has not been established yet.
Recently, several researchers have attempted to apply induced pluripotent stem cell (iPSC) technology as
a powerful tool for studying the mechanisms underlying the onset of various diseases and for new drug
screening. This technology has made an enormous breakthrough, since it permits us to recapitulate the
disease phenotype in vitro, outside of the patient's body. Here, we discuss the latest ﬁndings that
uncovered a mechanism underlying the pathology of a rare genetic musculoskeletal disease, ﬁbrodys-
plasia ossiﬁcans progressiva (FOP), by modeling the phenotypes with FOP patient-derived iPSCs, and that
discovered promising candidate drugs for FOP treatment. We also discussed future directions of FOP
research.
© 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2. Studying FOP with patient-derived iPSCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.1. Modeling FOP phenotypes with patient-derived iPSCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.2. Mechanisms underlying the phenotype of FOP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3. Discovering the candidate drugs for FOP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Study approval . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Conflicts of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
1. Introduction
Discovering a newdrug requires tremendous efforts. Typically, it
involves a long period of over ten years and massive costs, such as
over a hundred million US dollars [1e5]. After the long-term
developmental process including identiﬁcation of the target
molecule, screening and optimization of the compound, pharma-
cokinetic test, preclinical test, and clinical trial, the stage of a new
drug application is ﬁnally reached. Most of the compounds drop out
before the preclinical phase; thus, the probability of a compound
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reaching market as a new therapeutic agent is extremely low
[3,6e11]. Of late, signiﬁcant advances in computational sciences,
such as the appearance of super-computer, make it possible to
introduce several innovative technologies in the ﬁeld of medical
science. One such example is virtual in silico screening that simu-
lates and evaluates compound libraries computationally [12].
However, the number of new drug approvals is gradually declining
each year [13e16].
Induced pluripotent stem cell (iPSC) technology can also be used
for drug discovery research, besides regenerative medicine
[17e20]. Taking advantage of its pluripotency, various types of cells
constituting our body can be differentiated from iPSCs and used for
drug safety, toxicity, and pharmacokinetic assays. Moreover, this
technology can also be applicable to research on drug discovery in
case of intractable hereditary diseases for which no effective
treatment exists. For this purpose, disease-speciﬁc iPSCs with a
genetic background of a disease can be generated from patient-
derived cells [21,22]. This is a revolutionary advance as it enables
us to model the disease phenotypes in vitro outside of the patient's
body and to study the mechanisms underlying the onset of disease.
Although most of these studies used to depend on animal models
such as mice, the disease-speciﬁc iPSCs can also help to research on
diseases that have signiﬁcant species differences between humans
and mice [23e26].
Fibrodysplasia ossiﬁcans progressiva, FOP, is a rare genetic dis-
ease characterized by endochondral heterotopic ossiﬁcation in soft
tissues, including skeletal muscles, ligament, and tendon, where a
bone is not typically observed (Fig.1) [27e32]. Approximately 90% of
FOP patients share an R206H (617G > A) point mutation in the
intracellular glycine- and serine-rich domain of ACVR1, a type I re-
ceptor for bone morphogenetic proteins (BMPs) [33e37], and the
excessive transmission of the BMP signaling by mutant ACVR1
results in the bone formation ectopically [34,38e50]. This extra-
skeletal ossiﬁcation is often initiated between the infant and child-
hood stage; mean age at FOP diagnosis is 6.9 years [51], sometimes
accompanied by the hallux valgus, baldness, and hearing impair-
ment. Also, it is known that the ossiﬁcation often progresses
dramatically followed by ﬂare-up, inﬂammatory subcutaneous soft
tissue swelling, due to inﬂammation such as trauma, surgical inva-
sion, and infection. Ossiﬁcation starts mainly from the trunk region
and gradually tends to spread towards the periphery, thereby pro-
gressively decreasing the patient's exercise ability and function. The
bone formation in tissues related to respiration, such as thorax, or
in tissues related to chewing could lead to lifespan-shortening
[27e32]. At present, no effective treatment for FOP has been
approved. In this review, we discuss the latest ﬁndings in FOP
research using patient-derived iPSCs.
2. Studying FOP with patient-derived iPSCs
2.1. Modeling FOP phenotypes with patient-derived iPSCs
It is known that different donor tissues for generating iPSCs
could inﬂuence the nature of iPSCs because of the epigenetic
memory [52]. Thus, the robust differentiation method of human
iPSC-derived target cells and the generation of genetically matched
control iPSCs are needed to establish a successful in vitro model
using patient-derived iPSCs for the disease phenotypes.
During our body plan formation, skeletal tissues such as carti-
lages and bones originate from multiple developmental origins,
including neural crest cells, paraxial mesoderm cells, and lateral
plate mesoderm cells. These embryonic sources mainly give rise to
skeletal tissues in the cranial, trunk, and limb region, respectively,
at the postnatal state [53e60]. Several researchers have been trying
to generate iPSCs-derived cartilage and bone through various
developmental origins step by step, or directly from iPSCs [61e65].
Our previous studies have reported the establishment of neural
crest cell-derived and paraxial mesoderm cell-derived chon-
drocytes from human iPSCs [66e68].
Furthermore, we applied bacterial artiﬁcial chromosome (BAC)-
based homologous recombination technique to correct the FOP
mutation (617 G > A) existing in exon 7 of ACVR1, and reported the
establishment of mutation-rescued iPSCs (resFOP-iPSCs) from FOP
patient-derived iPSCs [69]. The resFOP-iPSCs could be used as
control iPSCs because they have the same genetic background as
FOP-iPSCs.
Using these materials, we elucidated the biology of FOP by
modeling the phenotypes in vitro. FOP-iPSCs showed increased
mineralization and cartilage formation compared to control healthy
iPSCs [38]. These results indicate that the FOP ACVR1 mutation
(R206H) favors chondrogenesis and increases mineral deposition
in vitro. Moreover, the mineralization phenotypes could be sup-
pressed with a small molecule inhibitor of BMP signaling, DMH1.
We also demonstrated that enhanced in vitro chondrogenic ability
of neural crest-derived mesenchymal stromal cells (MSCs; positive
for CD44, CD73, and CD105), induced from FOP-iPSCs, was tran-
scriptionally distinguishable from that of resFOP-iPSCs. SMAD1/5/8,
SMAD2/3, and ERK1/2 pathways were signiﬁcantly activated in
Fig. 1. Ectopic bone formation in FOP patients. Schematic view of ectopic bone formation observed in FOP patients. This ﬁgure is provided by Masaya Todani (Center for iPS Cell
Research and Application) and edited by authors.
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FOP-iPSC-derived MSCs (FOP-MSCs) [69]. We also performed a
genome-wide transcriptional analysis, and identiﬁed PAI1 and
MMP1 as key genes that are possibly associated with FOP onset and
phenotypes, by demonstrating that these were activated in
FOP-MSCs compared to resFOP-iPSC-derived MSCs (resFOP-MSCs),
and played a critical role during chondrogenesis.
Normally, the ectopic ossiﬁcation in FOP patients does not
appear at birth but starts to develop during childhood. We estab-
lished the iPSC differentiation method of sclerotome (SCL)-derived
embryonic chondrocytes and MSCs-derived chondrocytes through
the paraxial mesoderm, and compared the chondrogenic ability
using FOP-iPSCs/resFOP-iPSCs [67]. Consequently, enhanced chon-
drogenesis was observed in the MSC-derived chondrogenic
pathway as previously reported [69,70] but not in the SCL-derived
embryonic chondrogenic pathway. These observations imply the
cell-type speciﬁcity of FOP phenotypes, which possibly reﬂects the
onset of FOP.
2.2. Mechanisms underlying the phenotype of FOP
It has been shown that mutation in ACVR1, encoding a type I
receptor for BMP, is responsible for FOP [71]. There are several
proposed theories on the mechanism by which excessive BMP
signaling is transmitted downstream. In particular, there are two
major theories, stating that the signal is over-transmitted by the
BMP ligand binding to the mutant ACVR1, and that the signal is
constitutively activated regardless of the binding with BMP. How-
ever, the embryonic and postnatal skeletogenesis of FOP patients is
nearly normal although BMP signaling has a pivotal role during
human body development [28e30,32].
As an alternative to these canonical theories, in 2015 we advo-
cated a new hypothesis that a ligand which does not belong to the
BMP family binds to mutant ACVR1 and then transmits BMP
signaling instead. Due to this, bone/cartilage formation is abnor-
mally enhanced, leading to ectopic ossiﬁcation in FOP patients [70].
To screen ligands that activate BMP signaling through only mutant
ACVR1 but not wild-type ACVR, we introduced luciferase reporter
construct to both FOP-MSCs and resFOP-MSCs for detecting BMP
activity. These cells were treated with 27 different ligands having a
structure similar to BMP ligands, which belong to the TGF-b su-
perfamily. Then, the luciferase activity was measured in these
treated cells. Consequently, BMP signaling was activated to higher
levels in FOP-MSCs by the addition of several BMPs such as BMP 6
and BMP 7, as reported so far, but the ratio was approximately 1.4
times compared with resFOP-MSCs. Surprisingly, it was found that
the ratio dramatically increased more than 4 times only by activin
A, which belongs to the TGF-b superfamily, similar to BMPs. When
knocking down mutant ACVR1 in FOP-MSCs, activation of BMP
signaling was not observed. When mutant ACVR1 was overex-
pressed in another bone lineage cell; U2OS cells, BMP signaling was
activated in response to activin A. Furthermore, investigating the
effect of activin A on differentiation of iPSC-derived chondrocytes
revealed that the cartilage formation is enhanced by activin A
administration in FOP-MSCs. In addition, an ectopic bone was
formed after FOP-MSC transplantation with activin A-expressing
cells into immunodeﬁcient mice (Fig. 2).
Based on the above ﬁndings, it is elucidated that abnormal BMP
signaling transduction through mutant ACVR1 is caused by activin
A, a molecule that generally transmits TGF-b signaling and con-
tributes to inﬂammatory responses. Similar results were also re-
ported from another group [72]. This new ﬁnding supports and
coincides with the fact that patients usually show FOP symptoms
after trauma and/or inﬂammation. These discoveries also uncov-
ered a part of the pathological mechanism of FOP, which causes
ectopic bone tissue formation, and suggests a potential utilization
of anti-activin A-related compound as a drug candidate for FOP.
2.3. Discovering the candidate drugs for FOP
Given the adverse prognosis and the difﬁculty in surgical therapy
for FOP, developing an effective drug is strongly desired. Thus,
several researchers have been struggling for a breakthrough since a
long time. As candidate drugs for the disorders, which accompanied
heterotopic ossiﬁcation, several chemical compounds are proposed
e.g. inhibitors of BMP type I receptors, such as LDN193189 and
dorsomorphin which repress SMAD1/5/8 phosphorylation [73,74];
RARg agonists, which prevent the expression of SMAD1/5/8 [75];
hypoxia-inducible factor-1a inhibitor, which inhibit the production
of mesenchymal condensations [76]. Among them, Clementia
Pharmaceuticals Inc. have started a clinical trial that investigate the
curative effect of a RARg agonist; palovarotene on FOP patients.
Also, we reported a novel chemical screening system adopting
iPSC technologies and revealed a promising drug candidate, rapa-
mycin (international nonproprietary name; sirolimus), which could
prevent the development of ossiﬁcation in FOP patients [77]. We
established the screening system using FOP-MSCs harboring lucif-
erase following 5-repeats aggrecan enhancers tomonitor the activity
of chondrogenesis, and performed an initial screening against our
chemical library, containing 6809 compounds and assessed the
inhibitory effect on cartilage differentiation of FOP-MSCs. Then, a
second screening was done using 549 compounds that had been
evaluated to possess a certain effect at the ﬁrst screening, and
consequently, 76 compoundswere shortlisted after considering their
cytotoxicity. These hit compounds include RARg agonists and BMP
signaling inhibitors that have been reported previously [73e75], but
also include ﬁve mTOR inhibitors, suggesting the feasibility of mTOR
inhibitors in our system. Several researchers have addressed the
correlation of mTOR signaling and chondrogenesis as Chen and Long
reported that mammalian target of rapamycin complex 1 (mTORC1)
signaling controls skeletal growth through stimulation of protein
synthesis in chondrocytes [78]. Also, Lim et al., reported that Bmp
receptor type-1a controls osteoblast activity through mTORC1
signaling in mice, thus it is acceptable that mTOR signaling seems to
be a downstreameffector of Bmp signaling in skeletogenesis [79].We
subsequently investigated the effect of mTOR inhibitors using a
model of FOP-MSC transplant into mice to form ectopic bone, and
consequently found that the formation of ectopic bone by activin A
stimulation was suppressed by administering rapamycin (Fig. 3).
Therefore, these studies demonstrated the possible application of
rapamycin to treat FOP patients. Based on these research achieve-
ments, Kyoto University Hospital started an investigator-initiated
clinical trial that tests the curative effect on FOP patients in
September 2017. The efﬁcacy and safety are currently being assessed
by multicenter randomized double-blind placebo-controlled com-
parison test followed by open-label continuous administration.
In addition, we proposed another drug candidate for FOP with a
different model of chemical screening [80]. It is reported that
approximately half of FOP patients experienced the progression of
ectopic bone formation without apparent ﬂares or injury [51]. We
thus focused on the constitutive activity of mutated ACVR1 (FOP-
ACVR1) as well, and developed a high-throughput screening
system using a murine chondrogenic cell line, ATDC5, with
doxycycline-inducible human FOP-ACVR1. As several reports
demonstrated, ATDC5 is known to increase alkaline phosphatase
(ALP) expression following BMP stimulation, and ALP activity can
be monitored by a chromogenic phosphatase substrate in a
chemical screening format. Consequently, two candidate com-
pounds were identiﬁed from screening of 4892 compounds that
suppressed the enhanced chondrogenesis in FOP-iPSCs and that
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Fig. 2. Ectopic bones are formed following FOP-MSC transplantation. mCT images of formed ectopic bone in mice. FOP-MSCs (right leg) and resFOP-MSCs (left leg) were transplanted
into the gastrocnemius muscle of mice. White circles show the transplanted area. This ﬁgure has been modiﬁed from Hino et al. [70].
Fig. 3. Rapamycin suppresses ectopic bone formation. X-ray (upper row) and mCT (bottom row) images. Administration of rapamycin suppressed activin A-triggered ectopic bone
derived from FOP-MSCs. White arrows show the transplanted area. This ﬁgure has been modiﬁed from Hino et al. [77].
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suppressed the ectopic ossiﬁcation in multiple mouse models,
including FOP-ACVR1 transgenic mice and ectopic ossiﬁcation
model mice utilizing FOP-iPSCs. We also revealed that one of the hit
compounds, TAK 165, acts on mTOR indirectly, unlike rapamycin;
this indicates the possibility of mTOR signaling dysfunction as a
contributing factor in FOP and its possible application to the drug as
well. Although clinical trials using rapamycin have been in progress,
there is a substantial reason for considering a new drug, besides
rapamycin, since all patients do not have the same phenotype.
Moreover, it may be conceivable to achieve greater effects by
combining multiple drugs.
3. Conclusion
Rapamycin, an mTOR inhibitor, has already been used in Japan
as a drug for lymphangioleiomyomatosis. This concept of extended
application to the other disease is called drug repositioning. This
drug repositioning helps in reducing the cost and time of drug
development as compared to the canonical drug discovery
approaches [81]. The tag-team “iPSCs-technology based drug
discovery  drug repositioning” has great potential to accelerate
the process of discovering new therapeutic agents. In recent years,
this tag-team has revealed several drug candidates for diseases
other than FOP. For example, it is reported that statins, already
being used as therapeutic agents for hypercholesterolemia, can be
applied to the treatment for achondroplasia (bone lineage disorder)
and tanatophoric dysplasia as well [82]. In addition, another group
reported that bosutinib, an anticancer agent used for treating
chronic myelogenous leukemia, can also be used to treat amyo-
trophic lateral sclerosis, a type of neurodegenerative disease [83].
Moreover, it is demonstrated that rapamycin would be effective for
the treatment of Pendred syndrome, a hereditary disorder typically
associated with hearing loss [84].
Although rapamycin is expected to suppress the formation of
new ectopic bone in FOP cases, it cannot be effective for already
formed ectopic bone. In this regard, it is indispensable to develop
new drugs or treatments that can remove existing ectopic bone
tissue. Or adopting new therapeutic approaches such as genome-
editing for FOP treatment could be possible in future. Also,
several type of non-classic mutations that result in phenotypic
variations in terms of the severity and onset of disease are reported
but previous report have mainly used patient-derived iPSCs
harboring a classic FOP mutation, R206H. Thus, further progress in
research is still desired.
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